

# FASTNIB-FORTE TABLETS

Tofacitinib Citrate I.P. 11 mg

"Advanced JAK Inhibition for Severe Autoimmune & Inflammatory Disorders"

Marketed by: Human Orthocare

A Subsidiary of Human Biolife India Pvt. Ltd.

www.humanorthocare.com







# **Product Overview**

## Composition (per tablet):

Tofacitinib Citrate I.P. – 11 mg

## **Key Features:**

- Equivalent to *Tofacitinib XR 11 mg (extended release)*
- Once-daily dosing for better compliance
- Potent *Janus Kinase (JAK) inhibitor* → targets multiple cytokine pathways
- Effective oral therapy for moderate to severe autoimmune diseases

# **Mechanism of Action**



#### **JAK Inhibition**

Selectively inhibits JAK1 & JAK3, partially JAK2



### **STAT Pathway Blockade**

Blocks STAT pathway → reduces cytokine signalling (IL-2, IL-4, IL-6, IL-7, IL-15, IL-21, interferons)



### **Immune Suppression**

Suppresses immune hyperactivation & chronic inflammation

Result: Reduces joint damage, inflammation & systemic autoimmune activity



## Indications

Fastnib-Forte Tablets are recommended for:

#### **Rheumatoid Arthritis**

Moderate to severe cases requiring advanced therapy

#### **Psoriatic Arthritis**

Comprehensive treatment for joint and skin manifestations


### **Ankylosing Spondylitis**

Effective control of spinal inflammation and mobility

### **Ulcerative Colitis**

Moderate to severe inflammatory bowel disease

Other autoimmune disorders as per specialist guidance





# Clinical Advantages

Key Benefits of Fastnib-Forte:



### Once-Daily XR Dose

Better compliance versus 5 mg BID formulation. Extended release technology ensures consistent therapeutic levels throughout the day.



### **Enhanced Efficacy**

Stronger efficacy in severe or resistant autoimmune cases. Rapid onset of action with faster reduction in pain, swelling & stiffness.



#### **Convenient Alternative**

Oral therapy alternative to biologics - no injections required. Significantly improves patient function & quality of life.




# Comparison with Fastnib-5

Tofacitinib 5 mg BID versus 11 mg XR Once Daily

Parameter	Fastnib-Forte (11 mg XR OD)	Fastnib-5 (5 mg BID)
Dosing Frequency	✓ Once Daily	X Twice Daily
Compliance	✓ Better	<u>↑</u> Moderate
Efficacy in Severe RA/UC	✓ Stronger	1 Moderate
Monitoring Needs	Same (CBC, LFT, Lipids)	Same





#### Important Considerations:

- Avoid with strong immunosuppressants (biologics, cyclosporine)
- Regular monitoring: CBC, LFTs, lipid profile

# Dosage & Administration

## Standard Dosage

11 mg once daily (XR formulation)

Indicated for RA, PsA, AS & UC as per guidelines

## **Dose Adjustment**

Adjust dose in hepatic/renal impairment according to clinical guidelines



# **Safety & Tolerability**



#### **Common Side Effects**

- Headache
- Gastrointestinal upset
- Hypertension
- Increased cholesterol & liver enzyme levels


#### **Serious but Rare Risks**

- Opportunistic infections (TB, herpes zoster)
- Thrombosis & embolism (dose-related)
- Malignancy risk with long-term therapy

### Contraindications

- Severe hepatic impairment
- Active serious infections
- Pregnancy & lactation





# Why Prescribe Fastnib-Forte?

Doctor's Choice For:

Superior Compliance

Once-daily XR formulation significantly improves patient adherence compared to twice-daily dosing regimens

Enhanced Efficacy

Stronger efficacy in severe autoimmune conditions with rapid control of inflammation & joint damage

Treatment Alternative

Ideal for patients resistant or intolerant to conventional DMARDs or TNF inhibitors

Trusted Quality

Backed by the reliability and expertise of Human Orthocare





# Contact Us

Step into care that moves you forward.

Use with clinical discretion, especially in high-risk orthopedic conditions.

HumAn Orthocare – A Subsidiary of Human Biolife India Pvt. Ltd.

For medical queries or collaboration:



www.humanorthocare.com